OPSUMIT

This brand name is authorized in Austria, Australia, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug OPSUMIT contains one active pharmaceutical ingredient (API):

1 Macitentan
UNII Z9K9Y9WMVL - MACITENTAN

Macitentan is an orally active potent endothelin receptor antagonist, active on both ETA and ETB receptors. Endothelin (ET)-1 and its receptors (ETA and ETB) mediate a variety of effects such as vasoconstriction, fibrosis, proliferation, hypertrophy, and inflammation. In disease conditions such as PAH, the local ET system is upregulated and is involved in vascular hypertrophy and in organ damage.

Read about Macitentan

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
OPSUMIT Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C02KX04 C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KX Antihypertensives for pulmonary arterial hypertension
Discover more medicines within C02KX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 10134J, 10136L, 12135Q, 12147H
Country: CA Health Products and Food Branch Identifier(s): 02415690
Country: DE Bundesinstitut für Arzneimittel und Medizinprodukte Identifier(s): 10131105
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 2788-MEE-0517, 5042-MEE-0320
Country: EE Ravimiamet Identifier(s): 1636590, 1636602, 1842285
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 113893002
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 493464
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 237058
Country: HK Department of Health Drug Office Identifier(s): 64419
Country: IE Health Products Regulatory Authority Identifier(s): 88038
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7664
Country: JP 医薬品医療機器総合機構 Identifier(s): 2190035F1021
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1072544, 1072545, 1072546
Country: NL Z-Index G-Standaard, PRK Identifier(s): 115452
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 16347
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100312848
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W65300001
Country: SG Health Sciences Authority Identifier(s): 14809P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699593095467
Country: US FDA, National Drug Code Identifier(s): 66215-501

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.